A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Summary

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).

Timeline

Start

2021-05-24

Primary completion

2025-05-30

Completion

2026-03-18

Publications

• Socinski MA, Reck M, Paz-Ares L, Nishio M, Spira AI, Yu X, Melkadze T, Zeng A, Martinez-Bueno A, Li X, Arulananda S, Zuo Y, Chica-Duque S, Dai W, Zhou J, Tan W, Lu S. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 >/=50. J Thorac Oncol. 2026 Jul 14:104089. doi: 10.1016/j.jtho.2026.104089. Online ahead of print.

Drugs

Indications